📰 Noah Berkowitz News
Page 2 - Noah Berkowitz News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Noah Berkowitz. Real-time updates on events, politics, business and more.
March 3, 2023
Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission
November 1, 2022
Reblozyl, the first erythroid maturation agent showed increased haemoglobin in transfusion-dependant patients with myelodysplastic syndromes.
June 6, 2022
Bristol Myers Squibb announced the withdrawal of the sBLA for luspatercept-aamt for the treatment of anemia in adults with NTD beta thalassemia.
June 4, 2022
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company has withdrawn a supplemental biologics license application (sBLA) for Reblozyl® (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. The Company could not ap...
June 11, 2021
Reblozyl was generally well tolerated and improvements in hemoglobin correlated with improved patient-reported outcomes over a continuous 12-week interval In the study, 89.6% of patients treated with Reblozyl remained transfusion free vs. 67.3% of patients in the placebo arm at weeks 1-24 Results featured in Presidential Symposium of European Hematology Association’s Virtual Congress as one of top six abstracts submitted Bristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc....
June 11, 2021
BMS has reported positive data from the Phase III trial where Breyanzi met the primary endpoint in relapsed or refractory LBCL patients.
June 10, 2021
Study met primary and key secondary endpoints, demonstrating a highly statistically significant improvement in event-free survival, complete response rate and progression-free survival compared to standard of care Breyanzi safety results consistent with data from pivotal TRANSCEND NHL 001 trial Results represent the first time a therapy has demonstrated benefit compared to high-dose chemotherapy and stem cell ...
June 10, 2021
BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL. The trial met primary and key secondary endpoints, demonstrating a highly statistically significant impr...
April 23, 2021
If approved, Onureg will become the first and only once daily oral frontline maintenance therapy in Europe for patients with a broad range of acute myeloid leukemia subtypes In the pivotal QUAZAR ® AML-001 study, Onureg demonstrated significant overall survival and showed a relapse-free survival benefit in patients with AML in first remission Bristol Myers Squibb today announced the Committee for Medicinal Products … If approved, Onureg will become the first and only once daily oral frontli...